Deals
Deal Snapshot: The US giant has entered into an antibody biobucks deal with China's Harbour BioMed that could be worth over $1bn.
The bigger biopharma M&A deals seen particularly during the second half of 2025 should continue into 2026, PwC said, driven by LOEs and a more precision-driven process.
The France-based biotech is making solid progress amid mounting talk of a sale.
After buying the rights to Dren Bio’s lead candidate, DR-0201, in March, Sanofi has again tapped the start-up for a new drug discovery and development agreement for a potential new autoimmune therapy.
Despite recent setbacks in the field, big pharma still appears to have faith in the tau approach to Alzheimer's, as evidenced by Sanofi's new $1bn-plus deal with Korean venture ADEL for an early stage candidate.
Through its buyout of San Diego-based startup Arthrosi, Sobi gains the URAT1 inhibitor pozdeutinurad (AR882) for gout, which is an existing area of focus for the Swedish firm.
The deal, which could be worth as much as $1.7bn, looks to use Relation's AI capabilities to power the discovery of potentially first-in-class immuno-dermatology targets.
GSK builds up its arsenal of antibody-drug conjugates, while Oxford BioTherapeutics adds another pharma heavyweight to its expansive roster of partners.
To develop bispecific, dual-payload antibody-drug conjugates, Phrontline Biopharma’s strategy is to tune the activity of each payload to a similar level and engineer both toxins to fit within a branched linker, its CEO tells Scrip in an interview.
With its M&A war chest diminished and still seeking to add to its weight-management pipeline, Pfizer obtains an oral GLP-1 analog from Fosun subsidiary YaoPharma.
With three approved drugs and volixibat in pivotal studies for two cholestatic liver diseases, Mirum is betting $570m in cash and equity to pick up Bluejay’s Phase III hepatitis D candidate.
Plus deals involving Simcere/Vigonvita, Formosa/Rxilient, Shionogi/Japan Tobacco, Taiho/NEC/JFCR, Toray/Sanodyne, SK Biopharmaceuticals/WARF, BioCorteX/CD Biopharma, ToolGen/GenEditBio and Actimed/Mankind.
AstraZeneca quietly acquires Six Peaks, plus deals involving Bayer/Dare, Tempest/Factor, XenoTherapeutics/Repare, DayOne/Mersana and more.
Tessera, which claims its gene-writing technology offers functionality beyond gene-editing, hopes Regeneron can accelerate development of its preclinical alpha-1 antitrypsin deficiency drug.
Three big pharma business development heads at the recent Jefferies conference discussed their activities in 2025, and offered some advice to potential partners on how to avoid deal talks breaking down.
Lundbeck does not plan to raise its offer for sleep specialist Avadel, clearing the way for Alkermes to win the two-way bidding war.
Deal Snapshot: The US company has entered into another cancer drug transaction and bought Sprint's preclinical TREX1 program in a deal that could be worth around $400m.
Deal Snapshot: The biotech is joining forces with the Versant Ventures-backed startup, paying $50m upfront to apply its macrocycle peptide platform to immunological diseases.
Cidara’s long-acting antibody candidate could help protect millions of immunocompromised patients against flu – and could work around growing vaccine hesitancy in the US.
Hanmi is acquiring the Toronto-based biotech, Aptose, following positive early data of its lead asset tuspetinib in AML. The deal also gives Hanmi a strategic foothold in North America and marks another oncology-focused acquisition by a Korean pharma firm.